OrthoPediatrics (NASDAQ:KIDS) Director Sells $7,527,168.00 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 326,700 shares of OrthoPediatrics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the completion of the transaction, the director directly owned 6,536,764 shares of the company’s stock, valued at $150,607,042.56. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OrthoPediatrics Price Performance

NASDAQ KIDS traded down $0.31 on Tuesday, hitting $23.00. 139,797 shares of the company were exchanged, compared to its average volume of 173,766. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The firm has a 50 day moving average of $21.52 and a two-hundred day moving average of $18.72. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The company has a market cap of $600.53 million, a P/E ratio of -13.69 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. On average, equities analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on KIDS shares. Needham & Company LLC boosted their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research lifted their target price on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently modified their holdings of KIDS. BlackRock Inc. acquired a new position in OrthoPediatrics in the second quarter valued at approximately $24,347,000. Millennium Management LLC grew its holdings in OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after acquiring an additional 452,840 shares during the period. AIGH Capital Management LLC acquired a new stake in OrthoPediatrics during the 2nd quarter worth $5,161,000. Nantahala Capital Management LLC bought a new stake in shares of OrthoPediatrics during the 2nd quarter valued at $4,636,002. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics during the 2nd quarter valued at $4,537,000. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.